Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

WNT/β-catenin pathway activation correlates with immune exclusion across human cancers.

Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF.

Clin Cancer Res. 2019 Jan 11. pii: clincanres.1942.2018. doi: 10.1158/1078-0432.CCR-18-1942. [Epub ahead of print]

PMID:
30635339
2.

Optimization of Preclinical Metabolism for Somatostatin Receptor Subtype 5-Selective Antagonists.

Liu W, Hussain Z, Zang Y, Sweis RF, Romero FA, Finke PE, Moningka R, Bao J, Plotkin MA, Shang J, Dingley KH, Salituro G, Murphy BA, Howard AD, Ujjainwalla F, Wood HB, Duffy JL.

ACS Med Chem Lett. 2018 Oct 5;9(11):1088-1093. doi: 10.1021/acsmedchemlett.8b00306. eCollection 2018 Nov 8.

PMID:
30429950
3.

Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma.

Leng J, Akthar AS, Szmulewitz RZ, O'Donnell PH, Sweis RF, Pitroda SP, Smith N, Steinberg GD, Liauw SL.

Clin Genitourin Cancer. 2019 Feb;17(1):e12-e18. doi: 10.1016/j.clgc.2018.10.003. Epub 2018 Oct 12.

PMID:
30392939
4.

T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.

Trujillo JA, Sweis RF, Bao R, Luke JJ.

Cancer Immunol Res. 2018 Sep;6(9):990-1000. doi: 10.1158/2326-6066.CIR-18-0277.

PMID:
30181337
5.

Low clinical adoption of tumor genomic profiling: cause for concern?

Drazer MW, Sweis RF.

J Med Econ. 2018 Jul;21(7):721-723. doi: 10.1080/13696998.2018.1470978. Epub 2018 May 15. No abstract available.

PMID:
29708449
6.

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.

Sweis RF, Zha Y, Pass L, Heiss B, Chongsuwat T, Luke JJ, Gajewski TF, Szmulewitz R.

J Immunother Cancer. 2018 Apr 4;6(1):24. doi: 10.1186/s40425-018-0334-x.

7.

Erratum: The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.

He Y, Selvaraju S, Curtin ML, Jakob CG, Zhu H, Comess KM, Shaw B, The J, Lima-Fernandes E, Szewczyk MM, Cheng D, Klinge KL, Li HQ, Pliushchev M, Algire MA, Maag D, Guo J, Dietrich J, Panchal SC, Petros AM, Sweis RF, Torrent M, Bigelow LJ, Senisterra G, Li F, Kennedy S, Wu Q, Osterling DJ, Lindley DJ, Gao W, Galasinski S, Barsyte-Lovejoy D, Vedadi M, Buchanan FG, Arrowsmith CH, Chiang GG, Sun C, Pappano WN.

Nat Chem Biol. 2017 Jul 18;13(8):922. doi: 10.1038/nchembio0817-922b. No abstract available.

PMID:
28853738
8.

SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).

Curtin ML, Heyman HR, Clark RF, Sorensen BK, Doherty GA, Hansen TM, Frey RR, Sarris KA, Aguirre AL, Shrestha A, Tu N, Woller K, Pliushchev MA, Sweis RF, Cheng M, Wilsbacher JL, Kovar PJ, Guo J, Cheng D, Longenecker KL, Raich D, Korepanova AV, Soni NB, Algire MA, Richardson PL, Marin VL, Badagnani I, Vasudevan A, Buchanan FG, Maag D, Chiang GG, Tse C, Michaelides MR.

Bioorg Med Chem Lett. 2017 Aug 1;27(15):3317-3325. doi: 10.1016/j.bmcl.2017.06.018. Epub 2017 Jun 14.

PMID:
28610984
9.

Mechanistic and pharmacologic insights on immune checkpoint inhibitors.

Sweis RF, Luke JJ.

Pharmacol Res. 2017 Jun;120:1-9. doi: 10.1016/j.phrs.2017.03.012. Epub 2017 Mar 18. Review.

10.

SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding.

Curtin ML, Pliushchev MA, Li HQ, Torrent M, Dietrich JD, Jakob CG, Zhu H, Zhao H, Wang Y, Ji Z, Clark RF, Sarris KA, Selvaraju S, Shaw B, Algire MA, He Y, Richardson PL, Sweis RF, Sun C, Chiang GG, Michaelides MR.

Bioorg Med Chem Lett. 2017 Apr 1;27(7):1576-1583. doi: 10.1016/j.bmcl.2017.02.030. Epub 2017 Feb 20.

PMID:
28254486
11.

The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.

He Y, Selvaraju S, Curtin ML, Jakob CG, Zhu H, Comess KM, Shaw B, The J, Lima-Fernandes E, Szewczyk MM, Cheng D, Klinge KL, Li HQ, Pliushchev M, Algire MA, Maag D, Guo J, Dietrich J, Panchal SC, Petros AM, Sweis RF, Torrent M, Bigelow LJ, Senisterra G, Li F, Kennedy S, Wu Q, Osterling DJ, Lindley DJ, Gao W, Galasinski S, Barsyte-Lovejoy D, Vedadi M, Buchanan FG, Arrowsmith CH, Chiang GG, Sun C, Pappano WN.

Nat Chem Biol. 2017 Apr;13(4):389-395. doi: 10.1038/nchembio.2306. Epub 2017 Jan 30. Erratum in: Nat Chem Biol. 2017 Jul 18;13(8):922.

PMID:
28135237
12.

The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity.

Bromberg KD, Mitchell TR, Upadhyay AK, Jakob CG, Jhala MA, Comess KM, Lasko LM, Li C, Tuzon CT, Dai Y, Li F, Eram MS, Nuber A, Soni NB, Manaves V, Algire MA, Sweis RF, Torrent M, Schotta G, Sun C, Michaelides MR, Shoemaker AR, Arrowsmith CH, Brown PJ, Santhakumar V, Martin A, Rice JC, Chiang GG, Vedadi M, Barsyte-Lovejoy D, Pappano WN.

Nat Chem Biol. 2017 Mar;13(3):317-324. doi: 10.1038/nchembio.2282. Epub 2017 Jan 23.

PMID:
28114273
13.

Obviating the Need for Serial Biopsies Through Random Assignment.

Sweis RF, Ratain MJ.

J Clin Oncol. 2017 Jan 10;35(2):260. Epub 2016 Oct 31. No abstract available.

PMID:
28056195
14.

Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.

Guo L, Parker DL, Zang Y, Sweis RF, Liu W, Sherer EC, Buist N, Terebetski J, Kelly T, Bugianesi R, Priest BT, Dingley KH, Li X, Mitelman S, Salituro G, Trujillo ME, Pachanski M, Kirkland M, Powles MA, Eiermann GJ, Feng Y, Shang J, Howard AD, Ujjainwalla F, Sinz CJ, Debenham JS, Edmondson SD, Nargund RP, Hagmann WK, Li D.

ACS Med Chem Lett. 2016 Oct 12;7(12):1107-1111. eCollection 2016 Dec 8.

15.

Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.

Sweis RF, Galsky MD.

Urol Oncol. 2016 Dec;34(12):556-565. doi: 10.1016/j.urolonc.2016.10.006. Epub 2016 Nov 9. Review.

16.

Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma.

Sweis RF, Medved M, Towey S, Karczmar GS, Oto A, Szmulewitz RZ, O'Donnell PH, Fishkin P, Karrison T, Stadler WM.

Clin Genitourin Cancer. 2017 Apr;15(2):207-212. doi: 10.1016/j.clgc.2016.08.011. Epub 2016 Aug 17.

17.

Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer.

Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G, Gajewski TF.

Cancer Immunol Res. 2016 Jul;4(7):563-8. doi: 10.1158/2326-6066.CIR-15-0274. Epub 2016 May 17.

18.

Reply to T.A. Yap et al.

Sweis RF, Ratain MJ.

J Clin Oncol. 2016 Jul 10;34(20):2432-3. doi: 10.1200/JCO.2016.67.6163. Epub 2016 May 2. No abstract available.

PMID:
27138578
19.

Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer.

Sweis RF, Thomas S, Bank B, Fishkin P, Mooney C, Salgia R.

Cureus. 2016 Feb 26;8(2):e513. doi: 10.7759/cureus.513.

20.

Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.

Sweis RF, Drazer MW, Ratain MJ.

J Clin Oncol. 2016 Feb 1;34(4):369-74. doi: 10.1200/JCO.2015.63.6126. Epub 2015 Dec 14.

21.

The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.

Pappano WN, Guo J, He Y, Ferguson D, Jagadeeswaran S, Osterling DJ, Gao W, Spence JK, Pliushchev M, Sweis RF, Buchanan FG, Michaelides MR, Shoemaker AR, Tse C, Chiang GG.

PLoS One. 2015 Jul 6;10(7):e0131716. doi: 10.1371/journal.pone.0131716. eCollection 2015.

22.

Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2.

Sweis RF, Wang Z, Algire M, Arrowsmith CH, Brown PJ, Chiang GG, Guo J, Jakob CG, Kennedy S, Li F, Maag D, Shaw B, Soni NB, Vedadi M, Pappano WN.

ACS Med Chem Lett. 2015 Apr 29;6(6):695-700. doi: 10.1021/acsmedchemlett.5b00124. eCollection 2015 Jun 11.

23.

Target (In)Validation: A Critical, Sometimes Unheralded, Role of Modern Medicinal Chemistry.

Sweis RF.

ACS Med Chem Lett. 2015 May 21;6(6):618-21. doi: 10.1021/acsmedchemlett.5b00183. eCollection 2015 Jun 11.

24.

Do clinicians know which of their patients have central venous catheters?: a multicenter observational study.

Chopra V, Govindan S, Kuhn L, Ratz D, Sweis RF, Melin N, Thompson R, Tolan A, Barron J, Saint S.

Ann Intern Med. 2014 Oct 21;161(8):562-7. doi: 10.7326/M14-0703.

25.

Discovery and development of potent and selective inhibitors of histone methyltransferase g9a.

Sweis RF, Pliushchev M, Brown PJ, Guo J, Li F, Maag D, Petros AM, Soni NB, Tse C, Vedadi M, Michaelides MR, Chiang GG, Pappano WN.

ACS Med Chem Lett. 2014 Jan 2;5(2):205-9. doi: 10.1021/ml400496h. eCollection 2014 Feb 13.

26.

Tumor endothelial inflammation predicts clinical outcome in diverse human cancers.

Pitroda SP, Zhou T, Sweis RF, Filippo M, Labay E, Beckett MA, Mauceri HJ, Liang H, Darga TE, Perakis S, Khan SA, Sutton HG, Zhang W, Khodarev NN, Garcia JG, Weichselbaum RR.

PLoS One. 2012;7(10):e46104. doi: 10.1371/journal.pone.0046104. Epub 2012 Oct 4.

27.

Actinomyces-induced inflammatory pseudotumor of the lymph node mimicking scrofula.

Sweis RF, Propes MJ, Hyjek E.

Ann Intern Med. 2011 Jul 5;155(1):66-7. doi: 10.7326/0003-4819-155-1-201107050-00015. No abstract available.

PMID:
21727298
28.

2-(4-Carbonylphenyl)benzoxazole inhibitors of CETP: attenuation of hERG binding and improved HDLc-raising efficacy.

Sweis RF, Hunt JA, Sinclair PJ, Chen Y, Eveland SS, Guo Q, Hyland SA, Milot DP, Cumiskey AM, Latham M, Rosa R, Peterson L, Sparrow CP, Anderson MS.

Bioorg Med Chem Lett. 2011 May 1;21(9):2597-600. doi: 10.1016/j.bmcl.2011.02.049. Epub 2011 Feb 23.

PMID:
21398121
29.

2-(4-carbonylphenyl)benzoxazole inhibitors of CETP: scaffold design and advancement in HDLc-raising efficacy.

Sweis RF, Hunt JA, Kallashi F, Hammond ML, Chen Y, Eveland SS, Guo Q, Hyland SA, Milot DP, Cumiskey AM, Latham M, Rosa R, Peterson L, Sparrow CP, Wright SD, Anderson MS, Sinclair PJ.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1890-5. doi: 10.1016/j.bmcl.2010.11.090. Epub 2010 Nov 25.

PMID:
21147531
30.

Silver-catalyzed [2 + 2] cycloadditions of siloxy alkynes.

Sweis RF, Schramm MP, Kozmin SA.

J Am Chem Soc. 2004 Jun 23;126(24):7442-3.

PMID:
15198582
32.
33.

Cross-coupling reactions of organosilicon compounds: new concepts and recent advances.

Denmark SE, Sweis RF.

Chem Pharm Bull (Tokyo). 2002 Dec;50(12):1531-41. Review.

34.
35.

Cross-coupling reactions of alkenylsilanols with fluoroalkylsulfonates.

Denmark SE, Sweis RF.

Org Lett. 2002 Oct 17;4(21):3771-4.

PMID:
12375940
36.

Fluoride-free cross-coupling of organosilanols.

Denmark SE, Sweis RF.

J Am Chem Soc. 2001 Jul 4;123(26):6439-40. No abstract available.

PMID:
11427080

Supplemental Content

Loading ...
Support Center